The global systemic inflammatory response syndrome treatment market size was valued at US$ 11.97 billion in 2022 and to reach valuation US$ 25.84 billion by 2032 with a CAGR of 8% from 2023 to 2032.
The global systemic inflammatory response syndrome treatment market size was valued at US$ 11.97 billion in 2022 and to reach valuation US$ 25.84 billion by 2032 with a CAGR of 8% from 2023 to 2032.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/35701
Systemic inflammatory response syndrome (SIRS) is defined as a clinical response to a nonspecific onslaught of either infectious or noninfectious origin. SIRS is nonspecific and can be caused by ischemia, inflammation, trauma, infection, or several indications combined. Infection is a major cause of systemic inflammatory response syndrome; however, a number of other indications, including trauma, ARDS, neoplasm, burn injury, pancreatitis, and dysfunctional macrophage activation are also recognized causes.
A Key Driver
- Systemic inflammatory response syndrome SIRS is one of the major criteria for determining post-surgical complications and end-organ dysfunction. Development of the syndrome is related to long hospital stay, high incidence of multiple organ dysfunction, and increased morbidity.
- SIRS is among the common post-operative complications in cardiac surgery, leading to organ dysfunction or even death. The prevalence of SIRS among pediatric patients is expected to increase in the near future. An article published by the University of Colorado School of Medicine stated that, out of 56,210 visitors to emergency departments during a 1-year study period, 40,356 pediatric patients met inclusion criteria. Among the included study population, patients with SIRS vital signs accounted for 92.8% of all the visits with fever >38.5°C.
- An article published by the U.S. National Library of Medicine National Institutes of Health indicated that, out of 372,844,465 visits to the emergency department from 2007 to 2010, an estimated 17.8% ED visitors had SIRS, i.e., 16.6 million adult ED visits with SIRS per year. This retrospective study was conducted as a part of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for four years. The study concluded that SIRS is quite common among visitors to the ED.
- An article published by the American Academy of Neurology stated that, of the 780 patients with ICH, 21.8% developed non-infectious SIRS and 37.3% developed sepsis during hospitalization.
- Therefore, steady rise in the prevalence of SIRS is likely to drive the global systemic inflammatory response syndrome treatment market during the forecast period.
In terms of indication, the others segment held a major share of the global systemic inflammatory response syndrome treatment market in 2022. The segment is anticipated to dominate the market during the forecast period, owing to increased penetration. Based on end user, the hospitals & ambulatory surgical centers segment is expected to account for a significant share of the global systemic inflammatory response syndrome treatment market. The segment is likely to grow at a rapid pace during the forecast period. The hospitals & ambulatory surgical centers segment is projected to dominate the global market during the forecast period, due to increase in inpatient admissions in hospitals and ambulatory surgical centers. However, limited availability of therapeutics for SIRS and lack of quality care for critically-ill patients are anticipated to hamper the growth of the global SIRS treatment market during the forecast period.
Prominent Regions
North America held a major share of the global systemic inflammatory response syndrome treatment market in 2022. The market in the region is expected to grow at a rapid pace during the forecast period. The market in North America is driven primarily by a rise in the prevalence of SIRS and increase in knowledge about SIRS among healthcare professionals. Additionally, surge in government initiatives toward infectious & non-infectious diseases, increase in the geriatric population that is at high risk, and a large number of players in North America focusing on R&D activities to introduce technologically-advanced systemic inflammatory response syndrome treatments with improved designs propel the market in the region. The systemic inflammatory response syndrome treatment market in Asia Pacific is likely to witness strong growth. Asia Pacific is a relatively untapped market as compared to developed regions. Hence, the region offers immense opportunities to market players. Rise in the prevalence of SIRS, increase in knowledge about SIRS among healthcare professionals, growth of the healthcare industry, and awareness in the region fuel the growth of the SIRS treatment market in the region.
Europe held the second-largest market share in 2022. Well-developed healthcare infrastructure augments the systemic inflammatory response syndrome treatment market in the region. The markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future.
Related Reports
- Dry Eye Syndrome Treatment Market - https://www.visionresearchreports.com/dry-eye-syndrome-treatment-market/39754
- Polycystic Ovarian Syndrome Treatment Market - https://www.visionresearchreports.com/polycystic-ovarian-syndrome-treatment-market-size-share-trends-growth-production-consumption-revenue-company-analysis-and-forecast-2021-2030/37839
- Post-traumatic Stress Disorder Treatment Market - https://www.visionresearchreports.com/post-traumatic-stress-disorder-treatment-market/39888
Prominent players operating in the global SIRS treatment market include -
- CytoSorbents Corporation
- RegeneRx Biopharmaceuticals, Inc.
- Endacea, Inc.
- Adrenomed AG
- GlaxoSmithKline plc
- Asahi Kasei Corporation
- Cardinal Health
- Smith & Nephew plc
- ConvaTec, Inc.
- AstraZeneca
- Orion Corporation
- CHIESI Farmaceutici S.p.A.
- Mylan N.V.
Market Segmentation
By Indication
- Meningitis
- Urinary Tract Infection (UTI)
- Pneumonia
- Hemorrhage
- Autoimmune Diseases
- Others
By End User
- Hospital & Ambulatory Surgical Centers
- Specialty Clinics
- Others
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/35701
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/